Brand name drug companies are responsible for setting the prices of the prescription drugs in their portfolios. To maximize profits, at the expense of patients, taxpayers and the U.S. health care system, Big Pharma repeatedly hikes prices on existing products and sets increasingly outrageous launch prices on new medications.

Price-gouging, which leads to as many as one-in-two Americans experiencing financial hardship in affording prescription drugs, is enabled by Big Pharma’s egregious anti-competitive practices designed to extend monopolies and block patients from accessing more affordable alternatives, like generics and biosimilars.

Sep 2, 2026

NEW CSRxP ANALYSIS: BIG PHARMA SPENDS THREE TIMES MORE ON PROFITS, ADVERTISING AND OVERHEAD THAN R&D

Breaking Down The “Big Pharma Dollar” Shows Brand Name Pharmaceutical

Aug 25, 2026

CSRxP: BIG PHARMA HIKES PRICES ON NEARLY 250 PRESCRIPTION DRUGS IN LATEST ROUND OF MID-YEAR PRICE HIKES

Brand Name Drug Companies Maintain Business-as-Usual Approach to Price-Gouging